Lirentelimab（Cat No.:I042222）is a monoclonal antibody that targets the Siglec-8 receptor, primarily expressed on immune cells like mast cells and eosinophils, which are involved in allergic reactions and inflammation. By binding to Siglec-8, Lirentelimab inhibits the activation and accumulation of these cells, thereby reducing inflammation and allergic responses. It has been investigated for the treatment of diseases such as eosinophilic asthma, chronic rhinosinusitis with nasal polyps, and other allergic conditions. Clinical trials are exploring its safety and efficacy, with the goal of providing a targeted treatment for eosinophil-driven inflammatory diseases.
